211 related articles for article (PubMed ID: 27993660)
1. Much more than you expected: The non-DHFR-mediated effects of methotrexate.
Sramek M; Neradil J; Veselska R
Biochim Biophys Acta Gen Subj; 2017 Mar; 1861(3):499-503. PubMed ID: 27993660
[TBL] [Abstract][Full Text] [Related]
2. New mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of methotrexate in cancer cells.
Neradil J; Pavlasova G; Veselska R
Klin Onkol; 2012; 25 Suppl 2():2S87-92. PubMed ID: 23581023
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of resistance to antifolates, a review.
Banerjee D; Ercikan-Abali E; Waltham M; Schnieders B; Hochhauser D; Li WW; Fan J; Gorlick R; Goker E; Bertino JR
Acta Biochim Pol; 1995; 42(4):457-64. PubMed ID: 8852336
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate-based PROTACs as DHFR-specific chemical probes.
Rana S; Dranchak P; Dahlin JL; Lamy L; Li W; Oliphant E; Shrimp JH; Rajacharya GH; Tharakan R; Holland DO; Whitten AS; Wilson KM; Singh PK; Durum SK; Tao D; Rai G; Inglese J
Cell Chem Biol; 2024 Feb; 31(2):221-233.e14. PubMed ID: 37875111
[TBL] [Abstract][Full Text] [Related]
5. Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.
Goldman ID; Matherly LH
NCI Monogr; 1987; (5):17-26. PubMed ID: 2448654
[TBL] [Abstract][Full Text] [Related]
6. Cancer research: from folate antagonism to molecular targets.
Bertino JR
Best Pract Res Clin Haematol; 2009 Dec; 22(4):577-82. PubMed ID: 19959110
[TBL] [Abstract][Full Text] [Related]
7. Anticancer antifolates: current status and future directions.
McGuire JJ
Curr Pharm Des; 2003; 9(31):2593-613. PubMed ID: 14529544
[TBL] [Abstract][Full Text] [Related]
8. Further studies on the pharmacologic effects of the 7-hydroxy catabolite of methotrexate in the L1210 murine leukemia cell.
Seither RL; Rape TJ; Goldman ID
Biochem Pharmacol; 1989 Mar; 38(5):815-22. PubMed ID: 2467676
[TBL] [Abstract][Full Text] [Related]
9. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
10. Severe folate restriction results in depletion of and alteration in the composition of the intracellular folate pool, moderate sensitization to methotrexate and trimetrexate, upregulation of endogenous DHFR activity, and overexpression of metallothionein II and folate receptor alpha that, upon folate repletion, confer drug resistance to CHL cells.
Zhu WY; Bunni M; Priest DG; DiCapua JL; Dressler JM; Chen Z; Melera PW
J Exp Ther Oncol; 2002; 2(5):264-77. PubMed ID: 12416030
[TBL] [Abstract][Full Text] [Related]
11. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
Diddens H; Niethammer D; Jackson RC
Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
[TBL] [Abstract][Full Text] [Related]
12. In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics.
Rana RM; Rampogu S; Abid NB; Zeb A; Parate S; Lee G; Yoon S; Kim Y; Kim D; Lee KW
Molecules; 2020 Jul; 25(15):. PubMed ID: 32752079
[TBL] [Abstract][Full Text] [Related]
13. Investigation on inhibitory effect of folic acid on methotrexate-induced epithelial-mesenchymal transition focusing on dihydrofolate reductase.
Kawami M; Honda N; Hara T; Yumoto R; Takano M
Drug Metab Pharmacokinet; 2019 Dec; 34(6):396-399. PubMed ID: 31601464
[TBL] [Abstract][Full Text] [Related]
14. Cell-cycle-dependent pharmacology of methotrexate in HL-60.
Yamauchi A; Ichimiya T; Inoue K; Taguchi Y; Matsunaga N; Koyanagi S; Fukagawa T; Aramaki H; Higuchi S; Ohdo S
J Pharmacol Sci; 2005 Dec; 99(4):335-41. PubMed ID: 16327215
[TBL] [Abstract][Full Text] [Related]
15. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Chen G; Wright JE; Rosowsky A
Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
[TBL] [Abstract][Full Text] [Related]
16. A fluorescence study of substrate and inhibitor binding to bovine liver dihydrofolate reductase.
Degan P; Carpano P; Cercignani G; Montagnoli G
Int J Biochem; 1989; 21(3):291-5. PubMed ID: 2744204
[TBL] [Abstract][Full Text] [Related]
17. Metabolic inhibition by a new antifolate, 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-d]pyrimidine (BW3O1U), an effective inhibitor of human lymphoid and dihydrofolate reductase-overproducing mouse cell lines.
Sedwick WD; Hamrell M; Brown OE; Laszlo J
Mol Pharmacol; 1982 Nov; 22(3):766-70. PubMed ID: 7155133
[TBL] [Abstract][Full Text] [Related]
18. In vitro screening of biochemical activity of folic acid antagonists in skin.
McCullough JL; Weinstein GD; Hynes JB
J Invest Dermatol; 1977 Jun; 68(6):362-5. PubMed ID: 864277
[TBL] [Abstract][Full Text] [Related]
19. Characterization and comparative studies of zebrafish and human recombinant dihydrofolate reductases--inhibition by folic acid and polyphenols.
Kao TT; Wang KC; Chang WN; Lin CY; Chen BH; Wu HL; Shi GY; Tsai JN; Fu TF
Drug Metab Dispos; 2008 Mar; 36(3):508-16. PubMed ID: 18056255
[TBL] [Abstract][Full Text] [Related]
20. Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application.
McIvor RS
Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S50-4. PubMed ID: 8971409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
